Stock Performance: Globus Medical's stock has seen significant fluctuations, with a recent 2.6% decline following a 43.9% increase over the past month, while maintaining gains of 23.8% over three years and 48.3% over five years.
Valuation Concerns: The company scores only 2/6 on valuation checks, with a Discounted Cash Flow (DCF) analysis suggesting it is overvalued by approximately 414.3%, estimating an intrinsic value of $17.26 per share compared to its current trading price of around $88.
PE Ratio Analysis: Globus Medical's price-to-earnings (PE) ratio is about 28.0x, which is in line with the industry average but above its fair ratio of 23.8x, indicating that the stock may be expensively valued based on its earnings growth outlook.
Narrative Approach to Valuation: Investors can create personalized narratives about Globus Medical's future performance, which can lead to varying fair value estimates, ranging from $65 to $106 per share, depending on assumptions about growth and risks.
Wall Street analysts forecast GMED stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMED is 101.00 USD with a low forecast of 87.00 USD and a high forecast of 114.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast GMED stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMED is 101.00 USD with a low forecast of 87.00 USD and a high forecast of 114.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
4 Hold
0 Sell
Moderate Buy
Current: 94.150
Low
87.00
Averages
101.00
High
114.00
Current: 94.150
Low
87.00
Averages
101.00
High
114.00
Canaccord
Buy
maintain
$105 -> $112
2026-01-09
Reason
Canaccord
Price Target
$105 -> $112
AI Analysis
2026-01-09
maintain
Buy
Reason
Canaccord raised the firm's price target on Globus Medical to $112 from $105 and keeps a Buy rating on the shares. The firm updatedits model to reflect its Q4 preliminary results while noting Nevro preliminary Q4/25 implied revenue was significantly above the firm's $88.8M estimate, coming in at $99.9M.
Piper Sandler
Matt O'Brien
Overweight
maintain
$90 -> $115
2026-01-08
Reason
Piper Sandler
Matt O'Brien
Price Target
$90 -> $115
2026-01-08
maintain
Overweight
Reason
Piper Sandler analyst Matt O'Brien raised the firm's price target on Globus Medical to $115 from $90 and keeps an Overweight rating on the shares. The firm notes the company preannounced Q4 revenue of $823.2M, which comes in well above the Street's $778.5M estimate. While the company did not specifically break out Enabling Technology revenue, it did disclose "best quarterly revenue to date" which is a clear positive and, although they are not completely out of the woods yet, signals that things are starting to pick back up again, Piper argues.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GMED
Unlock Now
Canaccord
Caitlin Cronin
Buy
upgrade
$90 -> $105
2025-12-17
Reason
Canaccord
Caitlin Cronin
Price Target
$90 -> $105
2025-12-17
upgrade
Buy
Reason
Canaccord analyst Caitlin Cronin raised the firm's price target on Globus Medical to $105 from $90 and keeps a Buy rating on the shares. The firm said they are bullish on the Med-Tech sector heading into 2026 as they expect investor interest given smid-cap valuations continue to remain depressed, while M&A has picked up and the IPO market has opened in some respects. They also highlight how AI is changing our space, enabling improved patient outcomes, increased procedure volumes, more efficiency at the corporate level, and improved surgical accuracy/reproducibility, which they believe could drive some of the greatest changes in healthcare at a time when the system is capacity constrained and in desperate need of solutions.
RBC Capital
Shagun Singh
Outperform
maintain
$92 -> $100
2025-12-17
Reason
RBC Capital
Shagun Singh
Price Target
$92 -> $100
2025-12-17
maintain
Outperform
Reason
RBC Capital analyst Shagun Singh raised the firm's price target on Globus Medical to $100 from $92 and keeps an Outperform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC believes it is poised to deliver a solid year of underlying sales growth, estimating 4%-5% y/y growth as the initial target in a low-single-digit growth market that is likely to prove conservative.
About GMED
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions with a focus on improving the quality of life of patients with musculoskeletal disorders. The Company offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery techniques. It includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
